The World Health Organization has identified the development of a rapid point-of-care diagnostic test for Zika virus as a top research priority. In a recent Cell paper, Pardee et al. (2016) have exploited recent advances in synthetic biology and molecular engineering to deliver a sensitive, affordable, and field-ready Zika test.
Zika is a mosquito-borne viral disease that has had a dramatic global impact in recent times, especially in its association with severe congenital malformations in newborns and Guillain-Barre syndrome (Musso and Gubler, 2016) . Prior to 2007, only 15 cases of Zika had been documented since its discovery in Uganda in 1947. Its sudden emergence as a disease of pandemic proportions has been quite extraordinary, and why it has only recently gained traction with significant outbreaks in Micronesia, French Polynesia, and South America remains a mystery. While the disease mainly manifests as a febrile illness with rash, headache, joint pain, and conjunctivitis, there is a growing body of evidence to suggest that congenital abnormalities in infants, notably microcephaly, are linked to infection of the mother during pregnancy (Tang et al., 2016) . This has stimulated much concern and prompted Brazilian health authorities to declare the Zika outbreak a public health emergency.
The regions that are currently bearing the greatest burden of Zika disease are poorly resourced with limited health infrastructure. Thus, the need for an accurate system for the rapid diagnosis of Zika virus (ZIKV) infection that can be affordably implemented in basic clinics and health centers is paramount. Such a system would enable better patient management, particularly for timely monitoring of fetal development for women infected during pregnancy and to provide an earlier window for termination if needed. A rapid diagnostic would also provide early warning of transmission in communities to allow for rapid vector management and public awareness programs. The diagnostic is also critical to enhance the accuracy for exclusion of infected blood donations, as well as detection in sperm for people who are family planning (the virus has been detected in sperm up to 60 days after infection; Atkinson et al., 2016) . A rapid diagnostic would also enable earlier treatment intervention should effective therapies become available.
In their groundbreaking publication in Cell, Pardee and colleagues describe a strategy for developing programmable diagnostic assays for inclusion in portable devices. Building on their recently published ''toehold switch RNA sensor'' technology , which includes paper-based LacZ expression as a reporter system (Pardee et al., 2014) , the authors have incorporated isothermal nucleic acid amplification to provide a highly sophisticated test for ZIKV RNA that is rapid and sensitive but also suitable for use in a basic health facility at low cost.
The toehold switch sensor technology at the core of the assay comprises a synthetic mRNA that has its ribosome-binding site blocked by secondary structure. In the presence of ZIKV, viral RNA binds to the sensor and activates mRNA translation. Cell-free extracts embedded in paper provide the molecules to translate the mRNA, producing the well-known b-galactosidase enzyme, which reacts with its substrate to change the color of the paper (see Figure 1) . The toehold sensor is also intriguing as a programmable nucleic acid suitable for encoding molecular computing functions (e.g., see Poje et al., 2014) , which could be used to embed complex operations for autonomous or intelligent biosensing.
While the assay was highly discriminating for ZIKV when also assessed with the related Dengue viruses, the toehold sensor alone was not sufficiently sensitive to detect clinically relevant concentrations of ZIKV RNA. Fortunately, the nucleic acid sequence-based amplification (NASBA) system was seemingly purposely built to amplify low levels of viral RNA to suitable concentrations for activation of the toehold sensors. NASBA is also a particularly good choice for clinical applications, as it only requires incubation at a single low temperature (41 C) and is already commercially used in FDAapproved diagnostics, which reduces time to market compared to using an unverified technology (Li and Macdonald, 2015) .
NASBA is one of the slower isothermal amplification techniques in the market, adding an additional 2 hr to the assay; however, the final detection time of 3 hr is still a dramatic improvement on the current turnaround in Brazil, where samples are shipped to centralized laboratories that are already working at capacity. Due to current circumstances, pregnant women have to be prioritized, with a turnaround time of up to 3 weeks. For future development, it would be interesting to see if the assay time could be reduced even further by using other forms of isothermal RNA amplification such as recombinase polymerase amplification (James and Macdonald, 2015), which amplifies in 10 min (assuming the doublestranded DNA product could be converted to a single-stranded sensor input, perhaps through in vitro transcription).
An important outcome of this study is the provision of a full solution from sample to detection. Sample preparation remains one of the most challenging technological problems in the development of truly fieldbased molecular assays. The beauty of Pardee's method is that simply boiling the sample for 2 min effectively releases the viral RNA from clinical samples for detection by the NASBA-toehold sensor protocol. The authors provide an even more comprehensive vision of the field deployment of their diagnostic assay by describing the development of a portable, battery-powered reader to convert optical signals into electronic information. This is essential for true clinical implementation, as data need to be stored and transferred. It is also important given the 3 hr timeframe of the assay, which presumably allows for patients to be called or emailed the results rather than having to wait or come back for another appointment.
Another valuable addition to the specificity of the assay described in this paper is the power to differentiate between selected ZIKV strains. The implementation of the NASBA-CRISPR cleavage assay, which utilizes the nuclease activity of CRISPR/Cas9 to detect single nucleotide polymorphisms between ZIKV strains, creates a complete diagnostic package. Indeed, the ability to rapidly determine the ZIKV strain responsible for an infection may have huge significance, especially if the congenital neurological complications associated with in utero infection are associated with the emergence of a novel ZIKV strain (Faria et al., 2016) .
For the next phase of assay validation, it will be important to determine how well it performs with a range of samples from ZIKV-infected humans, including whole blood, serum, semen, urine, saliva, and plasma. Will the assay only detect ZIKV RNA in clinical samples collected during the few days of the acute phase of infection, or will the virus persist in detectable levels in bodily fluids such as semen and saliva? Either way, it is likely that low or trace levels of virus (<10 5 genome copies/mL) in these samples will be below the limit of detection of the assay based on the data presented by the authors. Thus, it would be wise to perform parallel testing for ZIKV-specific antibodies to provide evidence of infection for those individuals in whom the virus has already been cleared or reduced to trace levels by the immune response.
We eagerly await evaluation of the assay under field conditions. The vagaries of sample collection and storage should be assessed in follow-up studies to determine how red cell lysis, high fat content, and other issues interfere with the assay. Gauging the shelf life of the kits at ambient temperatures, particularly in high-humidity environments of tropical regions, will be another valuable test of the robustness of the system in remote, endemic areas.
Despite the outstanding significance and timely delivery of this innovative approach for Zika diagnosis, the most promising aspect of this report is the development of a complete pipeline for an easily programmable diagnostic system that could be rapidly optimized and applied to a myriad of infectious agents. This provides an incredibly fast and powerful response to outbreaks of new and emerging infectious diseases. This approach will also be particularly relevant for novel, uncultivable pathogens discovered by deep sequencing approaches.
